MedTrace Logo

Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients

NCT02225886 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-02-24

No results posted yet for this study

Summary

The administration of ascorbic acid seemed to increase the iron available for erythropoiesis, thus improving the anemia response to the treatment.

The investigators therefore aimed to evaluate the effects of intravenous ascorbic acid administration in hemodialysed patients with iron overload.

Conditions

  • Anaemia Response to the Treatment
  • Peripheral Iron Indices
  • Oxalemia

Interventions

DRUG

Ascorbic Acid

300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered

Sponsors & Collaborators

  • Anemia Working Group Romania

    lead OTHER

Principal Investigators

  • Gabriel Mircescu, Professor · Anemia Working Group Romania

  • Liliana Garneata, MD, PhD · Anemia Workiing Group Romania

  • Tudor Simionescu, MD, PhD · "Carol Davila" Teaching Hospital of Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2023-03-31
Completion
2023-12-31

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02225886 on ClinicalTrials.gov